AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 161 min read$TEVA

Kalif Eliyahu Sharon sold $3.6M of TEVA

Kalif Eliyahu Sharon (EVP, Chief Financial Officer) sold 106,563 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.10 ($3.63M total) on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kalif Eliyahu Sharon
Published Jun 16, 2026, 12:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The disclosure provides incremental information about insider behavior but does not introduce new operating or financial fundamentals for TEVA.

02

Market read

A CFO open-market sale worth ~$3.63M is disclosed; 10b5-1 status suggests limited fundamental implications.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, litigation, or operational updates, the signal is mostly sentiment and positioning rather than a catalyst.

Relevance 5/10Novelty 6/10Timing: SEC Form 4 filed 2026-06-16 for a 2026-06-11 sale

Background

The article is an SEC Form 4 insider transaction disclosure for TEVA, showing an officer sale executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

TEVA CFO Kalif Eliyahu Sharon sold 106,563 shares in an open-market transaction worth about $3.63M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but the transaction is explicitly pre-arranged (10b5-1), which typically dampens market reaction versus discretionary selling.

Market effects

Sector

No direct sector read-across; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on TEVA fundamentals.

Key entities

  • issuer
    TEVA

    TEVA Pharmaceutical Industries Ltd; subject of the insider transaction disclosure.

  • insider
    Kalif Eliyahu Sharon

    TEVA EVP and Chief Financial Officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min